NurPhoto / Getty Images
A $435 million Series C has pushed the anti-aging startup NewLimit's valuation to $3.1 billion — a figure that represents more than three times what the company was worth just twelve months ago, NewLimit announced. Founders Fund led the round, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital, alongside returning backers including Kleiner Perkins, Eli Lilly $LLY +1.73% Ventures, and Valor Equity Partners.
The South San Francisco company said it plans to launch its first human clinical trial next year, testing a liver cell-reprogramming therapy. NewLimit's approach uses epigenetic reprogramming — altering DNA markings that govern which genes a cell uses — to restore liver cells to a more youthful state. The company said its candidate has shown the ability to accelerate liver recovery from injury and improve tolerance of dietary and alcohol-related stress in preclinical models.
The accelerated timeline marks a sharp departure from earlier projections. When NewLimit raised a $130 million Series B in May 2025, executives said the first human trial might not occur until as late as 2030, according to The Wall Street Journal. NewLimit CEO and co-founder Jacob Kimmel said the discovery of a promising candidate late last year drove the change. "We started to get data that was far more compelling than we had ever expected at that point in time," Kimmel told Fierce Biotech.
